Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. ...
Seer, Inc. (NASDAQ: SEER) is a biotechnology company headquartered in Redwood City, California, founded in 2017 by Omid Farokhzad and Robert Langer. The company specializes in proteomics, offering the Proteograph Product Suite, an integrated platform including consumables, automated instrumentation, and software, enabling researchers to study the proteome at scale with ...Seer, Inc. (NASDAQ: SEER) is a biotechnology company headquartered in Redwood City, California, founded in 2017 by Omid Farokhzad and Robert Langer. The company specializes in proteomics, offering the Proteograph Product Suite, an integrated platform including consumables, automated instrumentation, and software, enabling researchers to study the proteome at scale with unbiased, deep coverage. Products are intended for research use only, not for diagnostic or clinical purposes. Seer collaborates with partners like Discovery Life Sciences and the Salk Institute, and serves academic, biopharmaceutical, and life science laboratories. As of the latest data, Seer has 124 employees and generates revenue around $14.2 million (2024), with a market cap of approximately $120 million. The company went public on December 4, 2020, on NASDAQ. Financially, Seer invests heavily in R&D, reflected in high R&D-to-revenue ratios, and has experienced operating losses typical for growth-stage biotech. Key personnel include co-founder and CEO Omid Farokhzad, a former Harvard Medical School professor, and co-founder Robert Langer, a renowned MIT professor. Seer aims to empower the scientific community by removing technological barriers to proteomic studies, potentially improving human health outcomes.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$16.1M
+15.6%
+14.6%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-73.6M
+15.0%
-0.4%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+49.7%
+1.4%
+46.8%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-483.9%
+32.6%
+14.9%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-456.6%
+26.5%
+12.4%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-46.2M
+6.9%
+39.0%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-286.9%
+19.5%
+46.8%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
9.1%
+15.1%
+4.0%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
12.84x
-22.3%
-16.8%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
Operator: Good day, and welcome to the Seer, Inc. Second Quarter 2026 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Marissa Bych with Gilmartin Group. Please go ahead.
Marissa Bych: Thank you. Earlier today, Seer released financial results for the quarter ended June 30, 2026. If you have not received this news release or if you would like to be added to the company's distribution list, please send an e-mail to investor@seer.bio. In addition, during today's conference call, we will be referencing a slide presentation that can be accessed on the Events and Presentations section of Seer's Investor Relations website. Participating today from Seer is Omid Farokhzad, Chief Executive Officer and Chair of the Board; and David Horn, Chief Financial Officer and President. Before we begin, I would like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section titled Forward-Looking Statements in the press release Seer issued today. For a more complete list and description, please see the Risk Factors section of the company's quarterly report on Form 10-Q for the quarter ended June 30, 2026, and its other filings with the Securities and Exchange Commission. Except as required by law, Seer disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast today. With that, I would like to turn the call over to Omid.
Omid Farokhzad: Thank you, Marissa, and thank you all for joining us this afternoon. I want to begin by acknowledging the ongoing efforts of the entire Seer team whose daily contributions propel us towards a future where proteomics can deliver a revolutionary impact for patients around the world. I've never been more excited than I am today about the differentiated value proposition of our Proteograph technology, the impact we will have and the market opportunities in front of us. Now let me walk you through where we stand. In the second quarter, we delivered a total revenue of $3.1 million, a step-up from our first quarter revenue and reflecting the ongoing pressures on academic funding. I want to be direct. Revenue at this stage does not reflect the value of what we're building. In nascent markets, technological advancement precedes commercial inflection. That is exactly where we are. The science and technology at Seer are delivering tangible value to customers and reinforcing our conviction in the opportunity ahead. With …
